Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Turkey.
Biomol Biomed. 2024 Mar 5;24(4):998-1003. doi: 10.17305/bb.2024.10255.
This study addresses the gap in understanding the prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression in metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor (VEGF)-based therapy. A retrospective multicenter study (n = 34) explored HIF-1 alpha expression via immunohistochemistry in patients treated with platinum chemotherapy and bevacizumab. Median progression-free survival (PFS) was significantly lower in the HIF-1 alpha low score group compared to the high score group (4.9 vs 12.9 months, P = 0.014). Similarly, the median overall survival (OS) was significantly reduced in the HIF-1 alpha low score group (8.3 vs 20.4 months, P = 0.006). This study, the first of its kind, highlights the prognostic significance of HIF-1 alpha expression in metastatic cervical SCC patients treated with bevacizumab-based therapy.
本研究旨在探讨缺氧诱导因子-1α（HIF-1α）表达在接受抗血管内皮生长因子（VEGF）治疗的转移性宫颈鳞状细胞癌（SCC）患者中的预后相关性。一项回顾性多中心研究（n=34）通过免疫组织化学方法检测接受铂类化疗和贝伐单抗治疗的患者中 HIF-1α的表达。HIF-1α低评分组的中位无进展生存期（PFS）明显低于高评分组（4.9 与 12.9 个月，P=0.014）。同样，HIF-1α低评分组的中位总生存期（OS）也明显降低（8.3 与 20.4 个月，P=0.006）。这是第一项此类研究，强调了 HIF-1α表达在接受贝伐单抗治疗的转移性宫颈 SCC 患者中的预后意义。
